期刊名称：EXPERIMENTAL HEMATOLOGY & ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and scope
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.
Open access
All articles published by Experimental Hematology & Oncology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Experimental Hematology & Oncology you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.
Article-processing charges
Open access publishing is not without costs. Experimental Hematology & Oncology therefore levies an article-processing charge of £1790.00/$2490.00/€2040.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
Indexing services
All articles published in Experimental Hematology & Oncology are included in:
- DOAJ
- Embase
- PubMed
- PubMed Central
- Science Citation Index Expanded
- SCImago
- Scopus
- Zetoc
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Instructions to Authors
Our 3-step submission process
-
Before you submit
Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit.
-
Ready to submit
To give your manuscript the best chance of publication, follow these policies and formatting guidelines.
-
Submit and promote
After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond.
Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.
Submit manuscript
Editorial Board
Editors-in-Chief
Dr Zihai Li, The Ohio State University, USA
Dr Delong Liu, New York Medical College, USA
Prof Kongming Wu, Tongji Medical College of Huazhong University of Science and Technology, China
Deputy Editor-in-Chief
Dr Chung-Tsen Hsueh, Loma Linda University, USA
Associate Editors
Prof Joachim Deeg, Fred Hutchinson Cancer Research Center, USA
Prof Andreas Engert, University Hospital of Cologne, Germany
Dr Sergio Giralt, Memorial Sloan Kettering Cancer Center, USA
Dr Elizabeth Jaffee, Johns Hopkins University, USA
Dr Lewis Silverman, Mt Sinai Medical Center, USA
Dr Pramod K. Srivastava, University of Connecticut, USA
Prof Yi-Long Wu, Guangdong General Hospital, China
Dr Cassian Yee, MD Anderson, USA
Dr RuiRong Yuan, University of Medicine and Dentistry of New Jersey, USA
Dr Lei Zheng, John Hopkins University, USA
Editorial Board
Prof Moulay A Alaoui-Jamali, Faculty of Medicine, McGill University, Canada
Dr Aristotle Bamias, University of Athens, Greece
Prof Gabriella Calviello, Università Cattolica del S. Cuore, Italy
Dr Shundong Cang, Henan Province People's Hospital, China
Prof Jang-Yang Chang, National Health Research Institutes, Taiwan
Dr. Ying-Jun Chang, Peking University People's Hospital, China
Dr Jeon-Hor Chen, University of California Irvine, USA
Prof Michelle YQ Chen, Zhongshan University, China
Prof Raymond L. Comenzo, Tufts Medical Center, USA
Dr Wei Dai, New York University, USA
Dr Adil Daud, University of California San Francisco, USA
Dr Wei Ding, Mayo Clinic, Rochester, NY, USA
Dr Harry Drabkin, Medical University of South Carolina, USA
Dr Konstantin Dragnev, Dartmouth-Hitchcock Medical Center, USA
Prof Eddy Hsueh, Saint Louis University, USA
Prof Jianda Hu, Fujian Medical University Union Hospital, China
Prof Xiao-Jun Huang, Peking University, China
Prof Peter E Huber, German Cancer Research Center, Germany
Dr Milind Javle, The University of Texas MD Anderson Cancer Center, USA
Yubin Kang, Medical University of South Carolina, USA
Prof Dan S Kaufman, University of California-San Diego, USA
Prof Won Seog WS Kim, Samsung Medical Center, South Korea
Prof Jin Li, Fudan University Shanghai Cancer Center, China
Prof Yangqiu Li, Guangzhou Jinan University, China
Prof Lisa Licitra, Istituto Nazionale Tumori, Italy
Dr Robert Lim, National University Cancer Institute, Singapore (NCIS), Singapore
Dr Shiaw-Yih Lin, The University of Texas MD Anderson Cancer Center, USA
Dr Loren Michel, Washington University, USA
Prof Jun Peng, Qilu Hospital of Shandong University, China
Prof Godefridus Peters, VU University Medical Center, Netherlands
Prof Robert Ramsay, Peter MacCallum Cancer Centre, Australia
Dr Mark Reeves, Loma Linda University, USA
Dr Yufang Shi, Institute of Health Sciences Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China
Dr Fabrice Soncin, Institut de Biologie de Lille, France
Dr Weijing Sun, University of Kansas, USA
Prof Heiichiro Udono, Okayama University, Japan
Dr Paraskevi Viviana Vogiatzi, University of Michigan Medical Center, USA
Dr Hongxia Wang, Shanghai Renji Hospital, China
Prof Jianmin Wang, Changhai Hospital, Second Military Medical University, China
Prof Jianxiang Wang, Chinese Academy of Medical Sciences, China
Dr Jörg Wischhusen, University of Wuerzburg, Germany
Dr Yu-Chung Wu, Veterans General Hospital-Taipei, Taiwan, Taiwan
Dr Binghe Xu, CAMS Cancer Hospital and Institute, China
Dr Xiao-Feng Yang, Temple University School of Medicine, USA
Dr Lanjing Zhang, University Medical Center at Princeton, USA
Dr Z Joe Zhao, University of Oklahoma Health Sciences Center, USA
Dr Ping Zhou, Tufts Medical Center, USA
Prof Christoph C Zielinski, Medical University Vienna, Austria
|
刊名字顺( Alphabetical List of Journals):
返回页首 